The Study of Clinical Profile of Patients With Mucormycosis During COVID-19 Pandemic in Tertiary Care Hospital.

Publication date: Oct 01, 2023

Mucormycosis has gained a huge number of cases in the second wave of post COVID-19 infection, which may be attributed to increased awareness, advancement in diagnostic techniques, and an increase in the prevalence of predisposing factors. This study evaluated the pattern, risk factors, and clinical profile of patients with mucormycosis during the second wave of the COVID-19 pandemic. A prospective observational study was conducted in the Department of Emergency Medicine of a dedicated tertiary care hospital for COVID-19. The Institutional Ethics Committee approved the study. One hundred five patients diagnosed with mucormycosis were included from June 2021 to December 2021. Informed consent was obtained from the patients. Data on demography, clinical features, predisposing factors, co-morbid conditions, and microbiological samples were obtained and analyzed. Out of 105 patients, 71 were male, and 34 were female. The patient presented with mucormycosis between the 2nd and 3rd week of post COVID-19 infection. Incidence was mainly seen in patients in their fifties, mostly associated with diabetes mellitus (DM) (53. 30%), oxygen administration (80%), and previous use of steroids (45. 71%). Predominantly, males were more affected. The most common presentation was headache (50. 47%), orbital pain with restricted ocular movement (47. 67%), proptosis (42. 85%), and diminished vision (41. 90%). Rhino-orbital-cerebral mucormycosis (ROCM) was the most common presentation of mucormycosis, while only five cases of pulmonary mucormycosis were found. ROCM was the most common presentation of mucormycosis between the second and third week of post COVID-19 infection. Diabetes mellitus and inadvertent use of steroids were major predisposing factors. Therefore, a high degree of suspicion and early diagnosis with initiation of treatment is warranted in cases of mucormycosis in post COVID-19 infection.

Open Access PDF

Concepts Keywords
December covid-19
Diabetes diabetes mellitus
Huge mucormycosis
June rhino-orbital-cerebral mucormycosis
Mucormycosis steroid


Type Source Name
disease MESH Mucormycosis
disease MESH COVID-19 Pandemic
disease MESH infection
disease MESH Emergency
disease MESH diabetes mellitus
drug DRUGBANK Oxygen
disease MESH proptosis
disease MESH diminished vision
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH cancer
disease MESH cardiovascular disease
disease MESH fungal infection
disease VO Fungi
drug DRUGBANK Dextrose unspecified form
disease MESH hyperglycemia
disease IDO blood
disease IDO immunosuppression
disease VO population
disease MESH zygomycosis
disease MESH morbidities
disease IDO history
drug DRUGBANK Corticorelin
disease VO organ
disease MESH AIDS
disease MESH carcinoma
disease MESH drug abuse
drug DRUGBANK Lactose
drug DRUGBANK Phenol

Original Article

(Visited 1 times, 1 visits today)